GlaxoSmithKline (LON:GSK) Issues Quarterly Earnings Results

GlaxoSmithKline (LON:GSK) released its earnings results on Wednesday. The company reported GBX 56.90 ($0.70) earnings per share for the quarter, Digital Look Earnings reports.

GSK stock opened at GBX 1,529.80 ($18.83) on Friday. GlaxoSmithKline has a fifty-two week low of GBX 16.27 ($0.20) and a fifty-two week high of GBX 1,857 ($22.85). The business’s 50 day moving average price is GBX 1,624 and its two-hundred day moving average price is GBX 1,636.23. The company has a debt-to-equity ratio of 159.26, a quick ratio of 0.54 and a current ratio of 0.87. The company has a market capitalization of $76.75 billion and a price-to-earnings ratio of 14.30.

The company also recently announced a dividend, which will be paid on Thursday, October 8th. Shareholders of record on Thursday, August 13th will be issued a dividend of GBX 19 ($0.23) per share. The ex-dividend date of this dividend is Thursday, August 13th. This represents a dividend yield of 1.22%. GlaxoSmithKline’s dividend payout ratio (DPR) is 71.03%.

A number of equities research analysts have recently weighed in on the company. Oddo Bhf reissued a “neutral” rating and issued a GBX 1,840 ($22.64) target price on shares of GlaxoSmithKline in a research note on Monday, June 22nd. UBS Group reissued a “buy” rating on shares of GlaxoSmithKline in a research note on Monday, July 27th. Liberum Capital reissued a “hold” rating on shares of GlaxoSmithKline in a research note on Thursday, May 28th. Jefferies Financial Group reissued a “buy” rating on shares of GlaxoSmithKline in a research note on Monday, June 29th. Finally, Goldman Sachs Group lowered their target price on GlaxoSmithKline from GBX 2,060 ($25.35) to GBX 2,020 ($24.86) and set a “buy” rating for the company in a research note on Friday. Three equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and six have given a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of GBX 1,832.24 ($22.55).

GlaxoSmithKline Company Profile

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.

Featured Story: What is the Book Value of a Share?

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.